

Shu-Chen Kuo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3954533/publications.pdf>

Version: 2024-02-01

138
papers

3,408
citations

136950

32
h-index

197818

49
g-index

139
all docs

139
docs citations

139
times ranked

5461
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Mortality and Major Adverse Cardiovascular Events in Sepsis Survivors. A Nationwide Population-based Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 209-217.	5.6	149
2	Emergence and Distribution of Plasmids Bearing the <i>bla</i> _{OXA-51} -Like Gene with an Upstream IS <i>Aba1</i> in Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates in Taiwan. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4575-4581.	3.2	125
3	Collateral Benefit of COVID-19 Control Measures on Influenza Activity, Taiwan. <i>Emerging Infectious Diseases</i> , 2020, 26, 1928-1930.	4.3	106
4	Association of Postdischarge Rehabilitation with Mortality in Intensive Care Unit Survivors of Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1003-1011.	5.6	97
5	Long-Term Clinical Outcome of Major Adverse Cardiac Events in Survivors of Infective Endocarditis. <i>Circulation</i> , 2014, 130, 1684-1691.	1.6	96
6	Impact of Appropriate Antimicrobial Therapy on Mortality Associated With <i>Acinetobacter baumannii</i> Bacteremia: Relation to Severity of Infection. <i>Clinical Infectious Diseases</i> , 2012, 55, 209-215.	5.8	92
7	Identification of novel vaccine candidates against <i>Acinetobacter baumannii</i> using reverse vaccinology. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1065-1073.	3.3	86
8	Emergence of extensively drug-resistant <i>Acinetobacter baumannii</i> complex over 10 years: Nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. <i>BMC Infectious Diseases</i> , 2012, 12, 200.	2.9	85
9	Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2015, 163, 663-672.	3.9	81
10	Emergence of Carbapenem-Resistant Non- <i>baumannii</i> Species of <i>Acinetobacter</i> Harboring <i>bla</i> _{OXA-51} -Like Gene That Is Intrinsic to <i>A. baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1124-1127.	3.2	79
11	Colistin resistance gene <i>mcr</i> -1 in <i>Escherichia coli</i> isolates from humans and retail meats, Taiwan. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2327-2329.	3.0	76
12	Risk factors and clinical outcomes of patients with carbapenem-resistant <i>Acinetobacter baumannii</i> bacteremia. <i>Journal of Microbiology, Immunology and Infection</i> , 2012, 45, 356-362.	3.1	75
13	Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation. <i>Circulation</i> , 2016, 133, 265-272.	1.6	69
14	Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. <i>Intensive Care Medicine</i> , 2015, 41, 806-813.	8.2	57
15	Rapid identification of <i>Acinetobacter baumannii</i> , <i>Acinetobacter nosocomialis</i> and <i>Acinetobacter pittii</i> with a multiplex PCR assay. <i>Journal of Medical Microbiology</i> , 2014, 63, 1154-1159.	1.8	50
16	Contribution of a Plasmid-Borne <i>bla</i> _{OXA-58} Gene with Its Hybrid Promoter Provided by IS <i>1006</i> and an IS <i>Aba3</i> -Like Element to β -Lactam Resistance in <i>Acinetobacter</i> Genomic Species 13TU. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3107-3112.	3.2	47
17	Clinical Antibiotic-resistant <i>Acinetobacter baumannii</i> Strains with Higher Susceptibility to Environmental Phages than Antibiotic-sensitive Strains. <i>Scientific Reports</i> , 2017, 7, 6319.	3.3	45
18	Levofloxacin-Resistant <i>Haemophilus influenzae</i> , Taiwan, 2004-2010. <i>Emerging Infectious Diseases</i> , 2014, 20, 1386-1390.	4.3	41

#	ARTICLE	IF	CITATIONS
19	Acinetobacter baumannii Extracellular OXA-58 Is Primarily and Selectively Released via Outer Membrane Vesicles after Sec-Dependent Periplasmic Translocation. Antimicrobial Agents and Chemotherapy, 2015, 59, 7346-7354.	3.2	41
20	Effect of the use of low and high potency statins and sepsis outcomes. Intensive Care Medicine, 2014, 40, 1509-1517.	8.2	39
21	Adverse Effects of Oral Nonselective and cyclooxygenase-2-Selective NSAIDs on Hospitalization for Acute Kidney Injury. Medicine (United States), 2016, 95, e2645.	1.0	39
22	Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients. American Heart Journal, 2017, 193, 1-7.	2.7	39
23	Association Between Recent Use of Proton Pump Inhibitors and Nontyphoid Salmonellosis: A Nested Case-Control Study. Clinical Infectious Diseases, 2014, 59, 1554-1558.	5.8	38
24	Association Between Recent Use of Fluoroquinolones and Rhegmatogenous Retinal Detachment: A Population-Based Cohort Study. Clinical Infectious Diseases, 2014, 58, 197-203.	5.8	36
25	<i>In Vivo</i> and <i>In Vitro</i> Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 4047-4054.	3.2	36
26	A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate. Vaccine, 2017, 35, 1440-1447.	3.8	36
27	Colistin nanoparticle assembly by coacervate complexation with polyanionic peptides for treating drug-resistant gram-negative bacteria. Acta Biomaterialia, 2018, 82, 133-142.	8.3	36
28	Dissemination of multidrug-resistant Acinetobacter baumannii carrying BlaOxA-23 from hospitals in central Taiwan. Journal of Microbiology, Immunology and Infection, 2013, 46, 419-424.	3.1	35
29	Sheltering Effect and Indirect Pathogenesis of Carbapenem-Resistant Acinetobacter baumannii in Polymicrobial Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3983-3990.	3.2	35
30	Diabetes mellitus is associated with acquisition and increased mortality in HIV-uninfected patients with cryptococcosis: A population-based study. Journal of Infection, 2016, 72, 608-614.	3.3	35
31	The impact of dialysis therapy on older patients with advanced chronic kidney disease: a nationwide population-based study. BMC Medicine, 2014, 12, 169.	5.5	34
32	Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Frontiers in Microbiology, 2015, 6, 231.	3.5	34
33	The Pattern of Cytokine Production In Vitro Induced by Ancient and Modern Beijing Mycobacterium tuberculosis Strains. PLoS ONE, 2014, 9, e94296.	2.5	33
34	Subnanometer Gold Clusters Adhere to Lipid A for Protection against Endotoxin-Induced Sepsis. Nano Letters, 2018, 18, 2864-2869.	9.1	33
35	Polymerase chain reaction assay for the detection of Acinetobacter baumannii in endotracheal aspirates from patients in the intensive care unit. Journal of Microbiology, Immunology and Infection, 2011, 44, 106-110.	3.1	32
36	Dissemination of imipenem-resistant Acinetobacter baumannii with new plasmid-borne bla OXA-72 in Taiwan. BMC Infectious Diseases, 2013, 13, 319.	2.9	32

#	ARTICLE	IF	CITATIONS
37	Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2604-2610.	3.6	32
38	Prediction of Patient Outcome from <i>Acinetobacter baumannii</i> Bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II Scores. <i>Internal Medicine</i> , 2011, 50, 871-877.	0.7	31
39	Biofilm formation is not associated with worse outcome in <i>Acinetobacter baumannii</i> bacteraemic pneumonia. <i>Scientific Reports</i> , 2018, 8, 7289.	3.3	30
40	Genetic Diversity of the <i>Mycobacterium tuberculosis</i> Beijing Family Based on SNP and VNTR Typing Profiles in Asian Countries. <i>PLoS ONE</i> , 2012, 7, e39792.	2.5	30
41	Association between Use of Oral Anti-Diabetic Drugs and the Risk of Sepsis: A Nested Case-Control Study. <i>Scientific Reports</i> , 2015, 5, 15260.	3.3	29
42	Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum β -lactamase-producing <i>Enterobacteriaceae</i> in a medical center in Taiwan: A prospective cohort study. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 168-174.	3.1	29
43	Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded <i>Acinetobacter baumannii</i> and Biofilm Architecture. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4670-4676.	3.2	28
44	Community-acquired bloodstream infections caused by <i>Acinetobacter baumannii</i> : A matched case-control study. <i>Journal of Microbiology, Immunology and Infection</i> , 2018, 51, 629-635.	3.1	28
45	An Outbreak of <i>Ralstonia pickettii</i> Bloodstream Infection Associated with an Intrinsically Contaminated Normal Saline Solution. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 444-448.	1.8	27
46	Risk of tuberculosis among healthcare workers in an intermediate-burden country: A nationwide population study. <i>Journal of Infection</i> , 2014, 69, 525-532.	3.3	26
47	Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β -lactamase-producing <i>Enterobacteriaceae</i> . <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 269-275.	3.1	25
48	Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders: A propensity score-matched follow-up study. <i>PLoS ONE</i> , 2019, 14, e0219172.	2.5	25
49	Comparison between bacteremia caused by carbapenem resistant <i>Acinetobacter baumannii</i> and <i>Acinetobacter nosocomialis</i> . <i>BMC Infectious Diseases</i> , 2013, 13, 311.	2.9	24
50	<i>Acinetobacter baumannii</i> nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients?. <i>BMC Infectious Diseases</i> , 2013, 13, 142.	2.9	24
51	Effective transfer of a 47 kb NDM-1-positive plasmid among <i>Acinetobacter</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2734-2738.	3.0	24
52	Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in <i>Acinetobacter baumannii</i> and <i>Acinetobacter</i> genomic species 13TU. <i>Journal of Microbiology, Immunology and Infection</i> , 2012, 45, 108-112.	3.1	23
53	Molecular Epidemiology of Emerging Carbapenem Resistance in <i>Acinetobacter nosocomialis</i> and <i>Acinetobacter pittii</i> in Taiwan, 2010 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	23
54	Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105883.	2.5	23

#	ARTICLE	IF	CITATIONS
55	Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 262-271.	4.5	22
56	Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. <i>Journal of Microbiology, Immunology and Infection</i> , 2011, 44, 45-51.	3.1	21
57	Comparison between bacteremia caused by <i>Acinetobacter pittii</i> and <i>Acinetobacter nosocomialis</i> . <i>Journal of Microbiology, Immunology and Infection</i> , 2017, 50, 62-67.	3.1	21
58	Completing Circular Bacterial Genomes With Assembly Complexity by Using a Sampling Strategy From a Single MinION Run With Barcoding. <i>Frontiers in Microbiology</i> , 2019, 10, 2068.	3.5	21
59	Associated clinical characteristics of patients with candidemia among different <i>Candida</i> species. <i>Journal of Microbiology, Immunology and Infection</i> , 2013, 46, 463-468.	3.1	20
60	Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with <i>Acinetobacter nosocomialis</i> bacteraemia. <i>Clinical Microbiology and Infection</i> , 2013, 19, 634-639.	6.0	20
61	Effect of diabetes mellitus on risk of latent TB infection in a high TB incidence area: a community-based study in Taiwan. <i>BMJ Open</i> , 2019, 9, e029948.	1.9	20
62	<i>In vitro</i> activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2071-2078.	3.0	20
63	Clonal Expansion of Both Modern and Ancient Genotypes of <i>Mycobacterium tuberculosis</i> in Southern Taiwan. <i>PLoS ONE</i> , 2012, 7, e43018.	2.5	20
64	Adding a C-terminal Cysteine (CTC) Can Enhance the Bactericidal Activity of Three Different Antimicrobial Peptides. <i>Frontiers in Microbiology</i> , 2018, 9, 1440.	3.5	19
65	Is Polymicrobial Bacteremia an Independent Risk Factor for Mortality in <i>Acinetobacter baumannii</i> Bacteremia?. <i>Journal of Clinical Medicine</i> , 2020, 9, 153.	2.4	19
66	Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated <i>Acinetobacter baumannii</i> complex in a medical center in Taiwan, 1997-2007. <i>Journal of Microbiology, Immunology and Infection</i> , 2011, 44, 358-363.	3.1	18
67	Incidence and outcome of newly-diagnosed tuberculosis in schizophrenics: a 12-year, nationwide, retrospective longitudinal study. <i>BMC Infectious Diseases</i> , 2013, 13, 351.	2.9	18
68	Association between previous history of gout attack and risk of deep vein thrombosis - a nationwide population-based cohort study. <i>Scientific Reports</i> , 2016, 6, 26541.	3.3	18
69	Increased <i>mcr-1</i> in pathogenic <i>Escherichia coli</i> from diseased swine, Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 751-756.	3.1	18
70	Risk factors for imipenem-nonsusceptible <i>Acinetobacter nosocomialis</i> bloodstream infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2014, 47, 311-317.	3.1	17
71	Efficacy of Tigecycline for Secondary <i>Acinetobacter</i> Bacteremia and Factors Associated with Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3637-3640.	3.2	17
72	Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure. <i>Heart</i> , 2017, 103, 414-420.	2.9	17

#	ARTICLE	IF	CITATIONS
73	Comparison between patients under hemodialysis with community-onset bacteremia caused by community-associated and healthcare-associated methicillin-resistant <i>Staphylococcus aureus</i> strains. <i>Journal of Microbiology, Immunology and Infection</i> , 2013, 46, 96-103.	3.1	16
74	A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of <i>Acinetobacter ursingii</i> . <i>BMC Infectious Diseases</i> , 2015, 15, 400.	2.9	16
75	Susceptibility of <i>Elizabethkingia</i> spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 653-658.	3.0	16
76	Association of Hypoglycemia With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes. <i>Medicine (United States)</i> , 2015, 94, e771.	1.0	15
77	Long-Term Outcomes in Critically Ill Septic Patients Who Survived Cardiopulmonary Resuscitation*. <i>Critical Care Medicine</i> , 2016, 44, 1067-1074.	0.9	15
78	Molecular Epidemiology of Emerging <i>bla</i> _{OXA-23-Like} - and <i>bla</i> _{OXA-24-Like} -Carrying <i>Acinetobacter baumannii</i> in Taiwan. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
79	Molecular epidemiology of <i>Mycobacterium tuberculosis</i> in aboriginal peoples of Taiwan, 2006–2011. <i>Journal of Infection</i> , 2014, 68, 332-337.	3.3	14
80	Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma. <i>BMC Cancer</i> , 2015, 15, 704.	2.6	14
81	The impact of chronic hepatitis B infection on major adverse cardiovascular events and all-cause mortality in patients with diabetes: a nationwide population-based study from Taiwan. <i>BMJ Open</i> , 2017, 7, e016179.	1.9	14
82	Bacteremia Due to <i>Acinetobacter</i> Genomic Species 10. <i>Journal of Clinical Microbiology</i> , 2010, 48, 586-590.	3.9	13
83	Comparison of microbiological and clinical characteristics based on SCCmec typing in patients with community-onset methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 22-26.	2.5	13
84	Evolution of carbapenem resistance in <i>Acinetobacter baumannii</i> : An 18-year longitudinal study from a medical center in northern Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 57-64.	3.1	13
85	Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients. <i>Medicine (United States)</i> 10.7843/14rgBT2/Overl	1.0	14
86	Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study. <i>Mayo Clinic Proceedings</i> , 2016, 91, 867-872.	3.0	12
87	Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study. <i>Journal of the American Medical Association</i> , 2016, 17, 59-64.	2.5	12
88	A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 1430-1434.	13.8	12
89	Nonpolio Enterovirus Activity during the COVID-19 Pandemic, Taiwan, 2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 306-308.	4.3	12
90	Antimicrobial Resistance Mechanisms and Virulence of Colistin- and Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolated from a Teaching Hospital in Taiwan. <i>Microorganisms</i> , 2021, 9, 1295.	3.6	12

#	ARTICLE	IF	CITATIONS
91	Molecular Epidemiology of Tuberculosis in Kaohsiung City Located at Southern Taiwan, 2000-2008. PLoS ONE, 2015, 10, e0117061.	2.5	11
92	Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy. Cmaj, 2016, 188, E148-E157.	2.0	11
93	Genetic diversity of the Mycobacterium tuberculosis East African-Indian family in three tropical Asian countries. Journal of Microbiology, Immunology and Infection, 2017, 50, 886-892.	3.1	11
94	Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study. PLoS ONE, 2019, 14, e0210479.	2.5	10
95	Emergence of mcr-1, mcr-3 and mcr-8 in clinical Klebsiella pneumoniae isolates in Taiwan. Clinical Microbiology and Infection, 2021, 27, 305-307.	6.0	10
96	Molecular epidemiology of carbapenem non-susceptible Acinetobacter nosocomialis in a medical center in Taiwan. Infection, Genetics and Evolution, 2015, 31, 305-311.	2.3	9
97	Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	9
98	Primary Small Cell Carcinoma of the Stomach Successfully Treated With Cisplatin and Etoposide. Journal of the Chinese Medical Association, 2009, 72, 598-602.	1.4	8
99	Antibiotic restriction policy paradoxically increased private drug consumptions outside Taiwan's National Health Insurance. Journal of Antimicrobial Chemotherapy, 2017, 72, 1544-1545.	3.0	8
100	Policy-driven revolution of prescription record in outpatient use of fluoroquinolones. Journal of Microbiology, Immunology and Infection, 2020, 53, 133-140.	3.1	8
101	Clinical and molecular characterization of Acinetobacter seifertii in Taiwan. Journal of Antimicrobial Chemotherapy, 2021, 76, 312-321.	3.0	8
102	Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia. PLoS ONE, 2016, 11, e0163271.	2.5	8
103	Bacterial membrane vesicles from <i>Acinetobacter baumannii</i> induced by ceftazidime are more virulent than those induced by imipenem. Virulence, 2020, 11, 145-158.	4.4	8
104	Predictors of mortality in surgical patients with Acinetobacter baumannii bacteremia. Journal of Microbiology, Immunology and Infection, 2011, 44, 209-214.	3.1	7
105	Clinical characteristics and prognostic factors of Acinetobacter nosocomialis bacteraemia in patients with solid tumours. Clinical Microbiology and Infection, 2012, 18, E373-E376.	6.0	7
106	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke. Journal of Hypertension, 2016, 34, 567-575.	0.5	7
107	Association between influenza vaccination and the reduced risk of acute kidney injury among older people: A nested case-control study. European Journal of Internal Medicine, 2018, 54, 65-69.	2.2	7
108	Confronting Tigecycline-Resistant Acinetobacter baumannii via Immunization Against Conserved Resistance Determinants. Frontiers in Microbiology, 2020, 11, 536.	3.5	7

#	ARTICLE	IF	CITATIONS
109	<i>In vitro</i> activity of SecA inhibitors in combination with carbapenems against carbapenem-hydrolysing class D β -lactamase-producing <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3441-3448.	3.0	6
110	Multicentre study of risk factors for mortality in patients with <i>Acinetobacter</i> bacteraemia receiving colistin treatment. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105956.	2.5	6
111	Risk of Mortality of Catheter-Related Bloodstream Infections Caused by <i>Acinetobacter</i> Species. <i>Journal of Intensive Care Medicine</i> , 2018, 33, 361-369.	2.8	5
112	A multicenter study on clinical characteristics of <i>Acinetobacter</i> bacteremia in patients with liver cirrhosis. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 956-965.	3.1	5
113	Influence of severity of infection on the effect of appropriate antimicrobial therapy for <i>Acinetobacter baumannii</i> bacteremic pneumonia. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 160.	4.1	5
114	Clinical and economic impact of intensive care unit-acquired bloodstream infections in Taiwan: a nationwide population-based retrospective cohort study. <i>BMJ Open</i> , 2020, 10, e037484.	1.9	5
115	Treatment of community-onset methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteremia: A hospital-based study. <i>Archives of Gerontology and Geriatrics</i> , 2012, 55, 152-156.	3.0	4
116	Sensitivity and specificity of Matrix-Associated Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) in discrimination at species level for <i>Acinetobacter</i> bacteremia. <i>Journal of Microbiological Methods</i> , 2017, 140, 58-60.	1.6	4
117	Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with <i>Acinetobacter</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	4
118	Early and Standard Urinary Catheter Removal After Gynecological Surgery for Benign Lesions: A Quasi-Experimental Study. <i>Clinical Nursing Research</i> , 2022, 31, 489-496.	1.6	4
119	Pregnant women with COVID-19. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2022, 61, 197-198.	1.3	4
120	Distinct Modes of Transmission of Tuberculosis in Aboriginal and Non-Aboriginal Populations in Taiwan. <i>PLoS ONE</i> , 2014, 9, e112633.	2.5	3
121	<i>In vitro</i> and <i>in vivo</i> activities of imipenem combined with BLI-489 against class D β -lactamase-producing <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 451-459.	3.0	3
122	Implementation and Effectiveness of a Bar Code-Based Transfusion Management System for Transfusion Safety in a Tertiary Hospital: Retrospective Quality Improvement Study. <i>JMIR Medical Informatics</i> , 2019, 7, e14192.	2.6	3
123	Visiting in disguise: Analysis of inpatient companions in the time of COVID-19. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 1111-1116.	1.4	3
124	Clinical characteristics of <i>Acinetobacter baumannii</i> complex bacteremia in patients receiving total parenteral nutrition. <i>Journal of the Chinese Medical Association</i> , 2012, 75, 102-108.	1.4	2
125	Rapid hypoglycemia onset associated with antimicrobial use in patients with diabetes: A nationwide population-based case-crossover study. <i>European Journal of Internal Medicine</i> , 2016, 34, e14-e15.	2.2	2
126	Impact of reduced tigecycline susceptibility on clinical outcomes of <i>Acinetobacter</i> bacteremia. <i>Journal of Microbiology, Immunology and Infection</i> , 2018, 51, 148-152.	3.1	2

#	ARTICLE	IF	CITATIONS
127	Effectiveness of coffee for postoperative ileus in patients following abdominal surgery: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 2072-2079.	1.7	2
128	A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. <i>Angewandte Chemie</i> , 2020, 132, 1446-1450.	2.0	2
129	The prediction values of carbapenemase detection methods and carbapenem susceptibility testing for clinical outcomes of patients with <i>Acinetobacter</i> bacteremia under carbapenem treatment. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 257-265.	3.1	2
130	<i>In vitro</i> and <i>in vivo</i> comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Chemotherapy</i> , 2022, 34, 166-172.	1.5	2
131	Risk factors and clinical outcome of <i>Acinetobacter</i> nonsusceptibility in monomicrobial <i>Acinetobacter nosocomialis</i> bacteremia. <i>Journal of Microbiology, Immunology and Infection</i> , 2016, 49, 371-377.	3.1	1
132	Plasmid- and chromosome-located <i>mcr-3</i> in <i>mcr-1</i> -positive <i>Escherichia coli</i> in Taiwan. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 105996.	2.5	1
133	Ser253Leu substitution in <i>PmrB</i> contributes to colistin resistance in clinical <i>Acinetobacter nosocomialis</i> . <i>Emerging Microbes and Infections</i> , 2021, 10, 1873-1880.	6.5	1
134	Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis. <i>BMJ Case Reports</i> , 2009, 2009, bcr0920080873-bcr0920080873.	0.5	1
135	Reply to Farioli and Kriebel. <i>Clinical Infectious Diseases</i> , 2014, 58, 1490-1490.	5.8	0
136	Frontispiece: A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. <i>Angewandte Chemie - International Edition</i> , 2020, 59, .	13.8	0
137	Frontispiz: A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. <i>Angewandte Chemie</i> , 2020, 132, .	2.0	0
138	Mobile resistomes of human pathogens in swine wastewater treatment plants. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 752-754.	3.1	0